# Who gets compared, and what gets counted?

> Trial choices | Sponsored Trials Evidence Review — Sponsored Trials Evidence Review compares the questions chosen for retatrutide, semaglutide, tesamorelin and KPV, including controls and sponsor disclosures.

**The agenda**

A placebo, another treatment and an empty delivery material can each make a useful opponent. They answer different questions.

## Placebo and active treatment

The [retatrutide diabetes trial](https://pubmed.ncbi.nlm.nih.gov/37385280/) included placebo and active control. Its published design makes the comparator an explicit choice. The [obesity trial](https://pubmed.ncbi.nlm.nih.gov/37366315/) gives the familiar weight comparison against placebo. The measurements in both papers are persuasive. I still examine which treatment-choice question each design answered.

In [SURMOUNT-5](https://pubmed.ncbi.nlm.nih.gov/40353578/), semaglutide and tirzepatide were compared directly for weight loss in adults with obesity. That is a useful addition to placebo evidence. It leaves comparisons of heart disease, kidney disease and longer-term safety to studies that actually measure those outcomes.

I distrust cross-trial league tables built from unrelated percentages. Different patients, durations and comparison groups can account for differences that the table quietly attributes entirely to the drug.

## Questions represented in this collection

| Study | People or model | Question measured |
|---|---|---|
| [Retatrutide obesity trial](https://pubmed.ncbi.nlm.nih.gov/37366315/) | Adults with obesity or overweight with a weight-related condition | Body-weight change versus placebo |
| [Semaglutide FLOW](https://pubmed.ncbi.nlm.nih.gov/38785209/) | Type 2 diabetes and chronic kidney disease | Combined serious kidney and death outcomes versus placebo |
| [Tesamorelin follow-up](https://pubmed.ncbi.nlm.nih.gov/18690162/) | Adults with HIV-associated abdominal fat accumulation | Visceral fat during continued treatment and after withdrawal |
| [KPV combination experiment](https://pubmed.ncbi.nlm.nih.gov/39211778/) | Mice with chemically induced colitis | Combination treatment compared with individual agents |

This collection reaches from serious illness in people to inflammation in mice. A single winner would depend on a question none of these papers asked. The [compound pages](/) give each intervention room for its actual result.

## Sponsor disclosures and publication rights

The funding declaration starts a useful inquiry into roles: who designed the protocol, held the data, performed the analysis and controlled submission for publication? The declaration can identify relationships; the methods and agreements are where the practical consequences may become clearer.

My concern is selective visibility. A sponsor’s preferred outcome can be a reasonable question, while a less flattering outcome may still matter enormously to patients. Results about adverse events, missing follow-up and treatment withdrawal deserve publication alongside efficacy.

An accusation of suppressed findings needs evidence of its own. Where a paper leaves a role unclear, my judgment on that role remains open. Financial involvement alone settles neither the reliability of the measurement nor the fairness of the public account.

## The next comparison

For retatrutide, I am waiting on durable health outcomes and better answers about stopping. Semaglutide already has [kidney](https://pubmed.ncbi.nlm.nih.gov/38785209/) and [cardiovascular](https://pubmed.ncbi.nlm.nih.gov/37952131/) outcome trials in defined patient groups. Tesamorelin’s [withdrawal finding](https://pubmed.ncbi.nlm.nih.gov/18690162/) makes maintenance central to its narrow approved purpose. KPV still needs basic human testing of a specified preparation.

Those are different research priorities. I judge a future trial by whether it fills one of those gaps, as well as by the size of its favorable result. The [reading list](/references) lets the original questions remain attached to their papers.

---

An independent peptide-trial briefing that audits sponsor roles and published evidence, never a clinic, placement service, or source of medical advice.